Advertisement: Cambridge Network
ARM Innovation Hub
RealVNC mid banner careers
Advertisement: CPL mid banner
Advertisement: Mobas mid banner
Advertisement: Barclays Eagle Labs
RealVNC mid-banner general
Advertisement: KISS
Advertisement: BKL
4 February, 2013 - 08:39 By Tony Quested

Antibodies boost in translational medicine race

Chairman and CEO, Andy Sandham

Cambridge antibody technology powerhouse, Kymab, has founded a global academic think tank to accelerate research into translational medicines.

The Kymab Access academic collaboration programme, steered from the UK, is designed to speed the discovery and development of human monoclonal antibodies.

Leading academic centres of excellence in translational medicine across the world will have the opportunity to evaluate new antibodies discovered on Kymab’s next generation platform.

Chairman and CEO, Andy Sandham, said that based on the new academic group’s understanding of disease biology, Kymab will use its Kymouse™ technology to discover lead antibodies for evaluation by academic partners.  

The Kymouse™ platform comprises a series of transgenic human antibody mouse strains designed to generate high quality, fully human, therapeutic antibodies with minimal requirement for subsequent engineering.                                                                                                                           Kymab Access will operate as an independent affiliate of the Cambridge company to ensure confidentiality of applications from academic groups.

A committee of leading academic researchers has been established to oversee the review of applications.

Sandham said: “We are looking forward to collaborating with academic groups that are experts in the biology of human disease and translational medicine.  

“Kymab is able to provide next generation human monoclonal antibodies to support these partnerships, in the quest to develop and commercialise innovative medicines.” Alliances with academia and industry could unlock huge potential for technology that was initiated at the Wellcome Trust Sanger Institute in Cambridge.

Sir Mark Walport, director of the Wellcome Trust, said: “Our investment in Kymab has allowed technology initiated at the Institute to deliver a world-leading human antibody discovery platform.

“We are committed to realising broad application of this technology to advance medical research and improve health, including tackling rare diseases and those affecting people in low and middle-income countries, through academic collaboration and industrial innovation.”

• More information on the programme can be found at

Add new comment

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features